All authors were employees of Roche at the time of the study. No authors have Conflicts of Interest information to declare.
Effect of Ritonavir-Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on QTc Interval in Healthy Subjects: Results from a Thorough QT Study
Version of Record online: 25 MAR 2013
© 2013 Wiley Periodicals, Inc.
Drug Development Research
Volume 74, Issue 5, pages 306–315, August 2013
How to Cite
Morcos, P. N., Kulkarni, R., Scoon, S., Smith, P. F. and Brennan, B. J. (2013), Effect of Ritonavir-Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on QTc Interval in Healthy Subjects: Results from a Thorough QT Study. Drug Dev. Res., 74: 306–315. doi: 10.1002/ddr.21080
Additional Supporting Information can be found in the online version of this article.
- Issue online: 12 JUL 2013
- Version of Record online: 25 MAR 2013
- Manuscript Accepted: 21 FEB 2013
- Manuscript Received: 29 JAN 2013
- Roche, Basel, Switzerland
Fig. S1. Placebo-adjusted change from baseline in (A) QTcB and (B) QTcF by trial treatment and time point (mean and 90% confidence interval). Dotted lines = 5- and 10-ms boundaries.
Fig. S2. Median moxifloxacin concentration–time profile (linear scale). MOXI, moxifloxacin.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.